Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Based on an average daily trading volume, of 421,900 shares, the days-to-cover ratio is currently 1.4 days. Currently, 22.4% of the company’s shares are sold short.

Aligos Therapeutics Stock Performance

ALGS opened at $24.27 on Thursday. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $46.80. The firm has a 50 day moving average price of $32.47 and a 200 day moving average price of $19.04. The company has a market cap of $87.13 million, a PE ratio of -1.83 and a beta of 2.50.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same quarter in the prior year, the firm earned ($10.25) earnings per share. On average, sell-side analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. AlphaMark Advisors LLC grew its stake in shares of Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares in the last quarter. Drive Wealth Management LLC purchased a new position in Aligos Therapeutics in the 4th quarter worth approximately $916,000. Finally, Golden State Wealth Management LLC purchased a new position in Aligos Therapeutics in the 4th quarter worth approximately $107,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).